US007825135B2

(12) **United States Patent**
Blackaby et al.

(10) **Patent No.: US 7,825,135 B2**
(45) **Date of Patent: Nov. 2, 2010**

(54) **HETEROARYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS**

(75) Inventors: **Wesley Blackaby**, Harlow (GB); **Mark E. Duggan**, Wellesley, MA (US); **David Hallett**, Harlow (GB); **George D. Hartman**, Landsdale, PA (US); **Andrew S. Jennings**, Harlow (GB); **William H. Leister**, Quakertown, PA (US); **Richard T. Lewis**, Harlow (GB); **Craig W. Lindsley**, Schwenksville, PA (US); **Elizabeth Naylor**, Harlow (GB); **Leslie J. Street**, Harlow (GB); **Yi Wang**, North Wales, PA (US); **David D. Wisnoski**, Quakertown, PA (US); **Scott E. Wolkenberg**, Jenkintown, PA (US); **Zhijian Zhao**, Wilimington, DE (US)

(73) Assignees: **Merck Sharp & Dohme Limited**, Hertfordshire (GB); **Merck Sharp & Dohme Corp.**, Rahway, NJ (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 91 days.

(21) Appl. No.: **10/593,950**

(22) PCT Filed: **Mar. 23, 2005**

(86) PCT No.: **PCT/US2005/009810**

§ 371 (c)(1), (2), (4) Date: **May 10, 2007**

(87) PCT Pub. No.: **WO2005/094514**

PCT Pub. Date: **Oct. 13, 2005**

(65) **Prior Publication Data**

US 2007/0254880 A1 Nov. 1, 2007

Related U.S. Application Data

(60) Provisional application No. 60/555,925, filed on Mar. 24, 2004.

(51) **Int. Cl.**
A61K 31/435 (2006.01)
A61K 31/445 (2006.01)

(52) **U.S. Cl.** **514/318**; 514/277

(58) **Field of Classification Search** ..... None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

6,664,273	B2 *	12/2003	Burnett et al.	514/327
2003/0013720	A1	1/2003	Hobbs et al.	
2006/0276655	A1	12/2006	Blackaby et al.	
2007/0105902	A1	5/2007	Lindsley et al.	
2007/0249606	A1	10/2007	Lindsley et al.	
2008/0021010	A1	1/2008	Lindsley et al.	
2008/0090796	A1	4/2008	Blackaby et al.	
2008/0108663	A1	5/2008	Lindsley et al.	

FOREIGN PATENT DOCUMENTS

WO WO 00/25786 * 5/2000

OTHER PUBLICATIONS

Wermuth (The Practice of Medicinal Chemistry, Academic Press, 1996, Chapter 13, pp. 203-238.*
Rogers et al (Brain Res, 493:41-50, 1989).*
Williams et al (Foye's Principles of Medicinal Chemistry, 5th Ed., 2002).*
Patani et al (Chem Rev 96:3147-3176, 1996).*
Wermuth C.G. The Practice of Medicinal Chemistry, Academic Press, (1996) Chapter 13, pp. 211-213.
Copending U.S. Appl. No. 11/922,074, filed Jun. 13, 2006, U.S. National Stage Entry of PCT/GB06/002156, published as WO 2006/134341.
Copending U.S. Appl. No. 11/991,727, filed Sep. 25, 2006, U.S. National Stage Entry of PCT/GB06/036989, published as WO 2007/041025.
Copending U.S. Appl. No. 12/084,027, filed Oct. 27, 2006, U.S. National Stage Entry of PCT/GB06/041699, published as WO 2007/053400.
Copending U.S. Appl. No. 12/085,340, filed Nov. 23, 2006, U.S. National Stage Entry of PCT/GB06/050411, published as WO 2007/060484.
Zhao et al., Bioorganic & Medicinal Chemistry Letters, 19 (2009) 1488-1491.
Lindsley et al., ChemMedChem 2006, 1, 807-811.

* cited by examiner

Primary Examiner—Brandon J Fetterolf
Assistant Examiner—Craig Ricci
(74) *Attorney, Agent, or Firm*—Gereard Devlin; Raynard Yurd

(57) **ABSTRACT**

The present invention is directed to pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl piperidine compounds that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurological and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine transporter GlyT1 is involved.

13 Claims, No Drawings